{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-015315","form_type":"8-K","ticker":"OBIO","cik":"0001814114","company_name":"Orchestra BioMed Holdings, Inc.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.275166+00:00","generated_at":"2026-05-16T02:48:43.691591+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Orchestra BioMed increases CEO base salary 4%, President/COO 10%; updates bonus plan and RSU vesting.","bullets":["CEO David Hochman base salary raised 4%; target bonus increased from 80% to 100% of base for 2026.","President/COO Mark Sherman base salary raised 10%; target bonus increased from 80% to 90% of base.","2026 bonus plan ties to clinical trial enrollment milestones for BACKBEAT and Virtue SAB studies.","RSU awards now vest 25% at 18, 24, 30, and 36 months; prior schedule changed.","CFO Andrew Taylor's bonus can be adjusted -45% to +0% based on individual performance objectives."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-015315","json":"https://secwatch.observer/filing/0001104659-26-015315.json","markdown":"https://secwatch.observer/filing/0001104659-26-015315.md","text":"https://secwatch.observer/filing/0001104659-26-015315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926015315/0001104659-26-015315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926015315/tm266305d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:48:43.691591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}